MarketBeat
25 Aug 2026, 01:03 UTC · 2h ago
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
25 Aug 2026, 01:03 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Bausch + Lomb estimates a combined potential peak sales value of over $2 billion for its dual-action dry eye treatment and the BL1332 pain candidate. — Provides a concrete, high-value revenue target that anchors the long-term valuation of the pipeline.
+0.60The dual-action dry eye treatment failed its primary endpoint at day 29 but showed statistically significant improvement at day 15, prompting a move to Phase III. — Mixed results create uncertainty; while the company is advancing, the failure of the primary endpoint increases the regulatory risk of the Phase III trial.
+0.30The Phase Ib study for the ocular pain candidate BL1332 met its primary endpoint, showing a statistically significant reduction in pain intensity compared to placebo. — Positive early-stage data validates the candidate's mechanism and supports further development in a high-need area.
+0.30Continue reading
6 related stories
Search tags
Management stated that neither the dry eye nor the pain program is expected to launch within the company's existing three-year plan. — Signals that these high-potential revenues are long-term prospects and will not contribute to near-term earnings growth.
-0.20Which stocks this story touches
Positive clinical results for ocular pain candidate BL1332 and promising, though mixed, Phase II results for a dry eye treatment with $2 billion in peak sales potential.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC Television
13h ago
